Logo image of TRDA

ENTRADA THERAPEUTICS INC (TRDA) Stock Fundamental Analysis

NASDAQ:TRDA - Nasdaq - US29384C1080 - Common Stock - Currency: USD

7.6  -0.3 (-3.8%)

After market: 7.6 0 (0%)

Fundamental Rating

4

TRDA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. While TRDA has a great health rating, its profitability is only average at the moment. TRDA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year TRDA was profitable.
TRDA had a negative operating cash flow in the past year.
In the past 5 years TRDA reported 4 times negative net income.
In the past 5 years TRDA reported 4 times negative operating cash flow.
TRDA Yearly Net Income VS EBIT VS OCF VS FCFTRDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

With an excellent Return On Assets value of 5.09%, TRDA belongs to the best of the industry, outperforming 92.50% of the companies in the same industry.
The Return On Equity of TRDA (5.94%) is better than 93.21% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.69%, TRDA belongs to the top of the industry, outperforming 91.79% of the companies in the same industry.
Industry RankSector Rank
ROA 5.09%
ROE 5.94%
ROIC 0.69%
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
TRDA Yearly ROA, ROE, ROICTRDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

With an excellent Profit Margin value of 14.39%, TRDA belongs to the best of the industry, outperforming 93.93% of the companies in the same industry.
Looking at the Operating Margin, with a value of 2.39%, TRDA belongs to the top of the industry, outperforming 92.14% of the companies in the same industry.
Industry RankSector Rank
OM 2.39%
PM (TTM) 14.39%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRDA Yearly Profit, Operating, Gross MarginsTRDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TRDA is destroying value.
Compared to 1 year ago, TRDA has more shares outstanding
Compared to 5 years ago, TRDA has more shares outstanding
TRDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TRDA Yearly Shares OutstandingTRDA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
TRDA Yearly Total Debt VS Total AssetsTRDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

TRDA has an Altman-Z score of 3.51. This indicates that TRDA is financially healthy and has little risk of bankruptcy at the moment.
TRDA has a better Altman-Z score (3.51) than 76.96% of its industry peers.
TRDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.51
ROIC/WACC0.07
WACC9.47%
TRDA Yearly LT Debt VS Equity VS FCFTRDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 21.88 indicates that TRDA has no problem at all paying its short term obligations.
The Current ratio of TRDA (21.88) is better than 95.54% of its industry peers.
TRDA has a Quick Ratio of 21.88. This indicates that TRDA is financially healthy and has no problem in meeting its short term obligations.
TRDA has a Quick ratio of 21.88. This is amongst the best in the industry. TRDA outperforms 95.54% of its industry peers.
Industry RankSector Rank
Current Ratio 21.88
Quick Ratio 21.88
TRDA Yearly Current Assets VS Current LiabilitesTRDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

TRDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.57%, which is quite impressive.
Looking at the last year, TRDA shows a small growth in Revenue. The Revenue has grown by 5.74% in the last year.
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.76%
Revenue 1Y (TTM)5.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-65.23%

3.2 Future

Based on estimates for the next years, TRDA will show a very strong growth in Earnings Per Share. The EPS will grow by 34.13% on average per year.
Based on estimates for the next years, TRDA will show a very negative growth in Revenue. The Revenue will decrease by -33.37% on average per year.
EPS Next Y-272.81%
EPS Next 2Y-105.9%
EPS Next 3Y-59.93%
EPS Next 5Y34.13%
Revenue Next Year-78.72%
Revenue Next 2Y-59.59%
Revenue Next 3Y-44.6%
Revenue Next 5Y-33.37%

3.3 Evolution

TRDA Yearly Revenue VS EstimatesTRDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
TRDA Yearly EPS VS EstimatesTRDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 5 -5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 9.38, the valuation of TRDA can be described as very reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of TRDA indicates a rather cheap valuation: TRDA is cheaper than 97.32% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of TRDA to the average of the S&P500 Index (26.25), we can say TRDA is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for TRDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 9.38
Fwd PE N/A
TRDA Price Earnings VS Forward Price EarningsTRDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -50.35
TRDA Per share dataTRDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as TRDA's earnings are expected to decrease with -59.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-105.9%
EPS Next 3Y-59.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTRADA THERAPEUTICS INC

NASDAQ:TRDA (5/30/2025, 8:00:01 PM)

After market: 7.6 0 (0%)

7.6

-0.3 (-3.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners85.05%
Inst Owner Change-1.54%
Ins Owners0.56%
Ins Owner Change22.33%
Market Cap288.42M
Analysts85.45
Price Target24.82 (226.58%)
Short Float %3.48%
Short Ratio7.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.1%
Min EPS beat(2)47.81%
Max EPS beat(2)104.39%
EPS beat(4)4
Avg EPS beat(4)288.27%
Min EPS beat(4)47.81%
Max EPS beat(4)948.01%
EPS beat(8)6
Avg EPS beat(8)190.15%
EPS beat(12)7
Avg EPS beat(12)116.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)138.81%
Min Revenue beat(2)98.17%
Max Revenue beat(2)179.44%
Revenue beat(4)4
Avg Revenue beat(4)108.71%
Min Revenue beat(4)55.73%
Max Revenue beat(4)179.44%
Revenue beat(8)8
Avg Revenue beat(8)153%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.2%
EPS NQ rev (1m)-3.1%
EPS NQ rev (3m)-12.75%
EPS NY rev (1m)5.05%
EPS NY rev (3m)-4.71%
Revenue NQ rev (1m)2.62%
Revenue NQ rev (3m)-18.54%
Revenue NY rev (1m)8.2%
Revenue NY rev (3m)-15.07%
Valuation
Industry RankSector Rank
PE 9.38
Fwd PE N/A
P/S 1.67
P/FCF N/A
P/OCF N/A
P/B 0.69
P/tB 0.69
EV/EBITDA -50.35
EPS(TTM)0.81
EY10.66%
EPS(NY)-4.28
Fwd EYN/A
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS4.54
BVpS10.99
TBVpS11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.09%
ROE 5.94%
ROCE 0.88%
ROIC 0.69%
ROICexc 3.79%
ROICexgc 3.79%
OM 2.39%
PM (TTM) 14.39%
GM N/A
FCFM N/A
ROA(3y)-8.83%
ROA(5y)-20.84%
ROE(3y)-10.65%
ROE(5y)-23.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 91.52%
Cap/Sales 2.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.88
Quick Ratio 21.88
Altman-Z 3.51
F-Score5
WACC9.47%
ROIC/WACC0.07
Cap/Depr(3y)144.47%
Cap/Depr(5y)309.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.76%
EPS Next Y-272.81%
EPS Next 2Y-105.9%
EPS Next 3Y-59.93%
EPS Next 5Y34.13%
Revenue 1Y (TTM)5.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-65.23%
Revenue Next Year-78.72%
Revenue Next 2Y-59.59%
Revenue Next 3Y-44.6%
Revenue Next 5Y-33.37%
EBIT growth 1Y-82.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-736.79%
EBIT Next 3Y-107.2%
EBIT Next 5YN/A
FCF growth 1Y-145.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.76%
OCF growth 3YN/A
OCF growth 5YN/A